What clinicians say about clinical trials, and why.
How oncologists read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question. Every view links to its source. Read the two-minute summary yourself, or let your AI agent work through the evidence.
Explore the report previews
| Trial | Indication | Phase | Statements | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| QUINTESSENTIAL-2Free NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Multiple myeloma | Phase 3 | 227 | 8 | Standard | Oct 9, 2026 | Preview |
| CheckMate 744 NCT02927769 · Bristol-Myers Squibb | Hodgkin lymphoma | Phase 2 | 197 | 19 | Standard | Oct 9, 2026 | Preview |
| PROUD-PV NCT01949805 · AOP Orphan Pharmaceuticals AG | Polycythemia vera | Phase 3 | 749 | 30 | Deep | Oct 8, 2026 | Preview |
| NEONIPIGA NCT04006262 · GERCOR - Multidisciplinary Oncology Cooperative Group | Gastroesophageal adenocarcinoma | Phase 2 | 1,222 | 60 | Deep | Oct 8, 2026 | Preview |
| CALGB-10403 NCT00558519 · Alliance for Clinical Trials in Oncology | Leukemia | Phase 2 | 1,065 | 28 | Deep | Oct 8, 2026 | Preview |
| MARS2 NCT02040272 · Royal Brompton & Harefield NHS Foundation Trust | Mesothelioma | Not applicable | 1,094 | 131 | Deep | Oct 8, 2026 | Preview |
| EURTAC NCT00446225 · Spanish Lung Cancer Group | Non-small cell lung cancer | Phase 3 | 210 | 9 | Standard | Oct 8, 2026 | Preview |
| SURTIME NCT01099423 · European Organisation for Research and Treatment of Cancer - EORTC | Renal cell carcinoma | Phase 3 | 427 | 32 | Deep | Oct 8, 2026 | Preview |
| MSLT-II NCT00297895 · Saint John's Cancer Institute | Melanoma | Not applicable | 499 | 36 | Deep | Oct 8, 2026 | Preview |
| EA3191 NCT04671667 · National Cancer Institute (NCI) | Head and neck squamous cell carcinoma | Phase 2 | 116 | 9 | Focused | Oct 7, 2026 | Preview |
10 of 10 reports
# What Erudio is and how to query it
curl https://www.erudio.com/llms.txt
# Every report, with counts, version and links
curl https://www.erudio.com/catalog.json
# One report as JSON or Markdown
curl https://www.erudio.com/reports/{slug}.json{
"mcpServers": {
"erudio": { "url": "https://mcp.erudio.com/mcp" }
}
}
# then ask your agent:
# search_reports({ "drug": "carboplatin" })- 10 published reports
- any listed oncology trial built within 24 hours
- weekly updates
- every statement source-linked
One trial, read three ways.
Every report has the same three parts, for you, for the colleagues you forward it to, and for your AI agent.
Executive summary
The two-minute read: how the clinicians who discussed the trial read it, where they differ, and the open question for Medical Affairs. A PDF to forward.
Detailed analysis
The reasoning, disagreements, qualifications and counterviews behind each finding, to read in your browser.
Structured evidence
Every verified HCP statement with its speaker, date, short quote and link, as JSON and through the Erudio MCP, so your agent can check any finding.
Follow a trial with weekly updates: when the commentary changes a finding you get a new edition and a note of what changed, and when nothing changes you get a dated note that the report is current.
Check our work before you buy.
What comparative benefit would distinguish target diversification from a clinically meaningful improvement over the trial's standard-care options?
- 01An attractive non-BCMA option, with superiority still an open question
- 02Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal
- 03Post-BCMA placement is attractive, but antigen switching is not an automatic rule
- 04Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure
The complete QUINTESSENTIAL-2 report is free: the executive summary, the analysis of every finding, and the verified HCP statements behind them, each linked to the podcast, video or post it came from. Trace any finding to its source.
227 verified HCP statements from 8 commentary sources · 9 findings · updated Oct 9, 2026
What you have today, and what Erudio adds.
Most teams already pay for some of these. Erudio fills the gap between them: the clinician's own reasoning about a trial, in public, with the source.
| You have | It gives you | Erudio adds |
|---|---|---|
| KOL and HCP databases | Who a clinician is: affiliations, publications, trials. | What they said about a trial, where and when, with their reasoning. Use both. |
| Social listening | Mentions and sentiment, mostly from short posts. | Long-form podcasts and video as well as X, with clinical views kept apart from reactions. |
| Field medical insights | What your MSLs heard in private conversations. | What clinicians say in public, with optional NPI and ORCID linkages to connect each voice to your expert records in Salesforce, Veeva or other NPI-keyed systems. It complements your field insights and never ingests them. |
| Agencies and congress reports | One question per project, in weeks. | A report on any listed trial within 24 hours, with every source linked, plus weekly updates. |
| General AI chat | Fast answers with uncertain sources. | Every statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps. |
Every report works with your agent. Enterprise adds the whole corpus.
One trial, one report, agent included
What clinicians said about a trial in podcasts, videos and posts, why their readings differ, and the source behind every view: an executive summary to forward, the analysis, and the evidence your AI agent can query, with no enterprise contract. Buy the current edition, or follow a trial with 3, 6 or 12 months of weekly updates. Trials without a report are built within 24 hours of your order.
The whole corpus, for your agents
Search across all the HCP podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses, from Microsoft Copilot, ChatGPT, Claude or your own agent. Ask “prep me for my meetings with these five oncologists” and get sourced answers.
How a report is built
Every report separates what clinicians said from what the primary evidence establishes. We never turn commentary into an efficacy verdict or a consensus.
- 01
Resolve the trial
One registry record, its aliases, no look-alikes
- 02
Gather sources
Podcasts, videos and X posts that name the trial
- 03
Screen and extract
Each view, question and reason becomes a statement
- 04
Audit
Every statement checked against its original passage
- 05
Compose
What clinicians said and why, beside the primary facts
- 06
Review
Findings checked for fidelity and overclaiming
- 07
Version and publish
A hashed, versioned edition with a changelog
- Read the methods →
Built around the jobs Medical Affairs already does.
Meeting prep
Readout reaction
Congress briefing
Advisory boards
Competitive context
Evidence gaps
Launch and access signals
Trial watchlist
Education needs assessment
Public sources only. Every statement linked. Every edition versioned, with corrections in the open.
- Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
- Co-founder Audun Utengen has published research with clinicians in BMJ, JAMA Oncology and the European Heart Journal
- Erudio Health has received a Security-only SOC 2 Type II report, available under NDA
- Reports state what they do not cover, on every page
- Non-promotional: no efficacy verdicts, consensus scores or rankings. Trust center